Used in the treatment of relapsed or refractory multiple myeloma, this antibody targets GPRC5D, a receptor highly expressed on malignant plasma cells. It engages T cells through a dual mechanism, redirecting them to attack cancer cells, leading to tumor cell lysis. Its application offers a therapeutic option for patients who have failed prior therapies, including those targeting BCMA. Administered intravenously or subcutaneously, it has shown clinical efficacy in reducing disease burden and inducing responses in heavily pretreated patients.